BL-M11D1
- Generic Name
- BL-M11D1
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06714591
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸START Midwest/The Cancer and Hematology Center, Grand Rapids, Michigan, United States
🇺🇸Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio, United States
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05924750
- Locations
- 🇨🇳
Shanghai Tongji Hospital, Shanghai, Shanghai, China
🇨🇳West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath